Additional research on metabolic phenotypes may elucidate distinct obesity subtypes (e.g., insulin resistance, dyslipidemia, or chronic inflammation) that may derive differential benefits from GLP-1 receptor agonist therapy. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.